This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Memorial Sloan Kettering Cancer Center, New York University. Active years: 2008.
Company Filing History:
1 out of 617 
1 out of 1,726 
Years Active: 2008
Title: David Polsky: Innovator in Melanoma Detection
Introduction
David Polsky is a notable inventor based in Ardsley, NY (US). He has made significant contributions to the field of cancer diagnostics, particularly in the detection of melanoma. His innovative work has the potential to improve patient outcomes through early detection and monitoring.
Latest Patents
David Polsky holds a patent for "Methods for detecting circulating mutant BRAF DNA." This invention relates to a method for detecting the presence of circulating mutant BRAF DNA, which may be present in circulating melanoma cells or as DNA shed from tumor cells. The patent presents methods, compositions, and kits that employ one or more sets of BRAF mutant specific primer pairs for the detection of circulating mutant BRAF DNA. Additionally, it provides methods for diagnosing and determining the stage or progression of melanoma in mammals based on the detection of a BRAF mutant nucleic acid sequence. These methods are well-suited for monitoring disease activity in patients with active disease or those in remission.
Career Highlights
Throughout his career, David Polsky has worked with prestigious institutions, including New York University and Memorial Sloan Kettering Cancer Center. His work has focused on advancing the understanding and treatment of melanoma, contributing to the development of innovative diagnostic methods.
Collaborations
David has collaborated with esteemed colleagues such as Iman Osman and Paul B. Chapman. Their combined expertise has furthered research in the field of cancer detection and treatment.
Conclusion
David Polsky's contributions to melanoma detection through his patented methods highlight his role as an innovator in the medical field. His work not only aids in the diagnosis of melanoma but also enhances the monitoring of disease progression, ultimately benefiting patient care.